A photo of Phillip Minar.

Associate Professor, UC Department of Pediatrics

513-636-4415

Board Certified

"Our goal is to personalize IBD care and prioritize building a strong relationship with the patient and family, which includes explaining the next steps in a way that all will understand. We also strive to be very responsive to the needs of the patient and their family."

My Biography & Research

Biography

I practice pediatric gastroenterology for children, adolescents and young adults with a special focus on those who have inflammatory bowel disease (IBD). This includes Crohn’s disease and ulcerative colitis.

Our goal is to personalize IBD care and prioritize building a strong relationship with the patient and family, which includes explaining the next steps in a way that all will understand. We also strive to be very responsive to the needs of the patient and their family. I factor in how the care model will affect the patient and family and offer a positive outlook to care. My nurse team and I lead by example — we love our jobs and want our patients to see that they can have hope, even when it doesn't seem possible with a chronic illness.

The primary focus of my research is to discover novel biomarkers specific for intestinal inflammation. My colleagues and I want to develop better tools using the latest technology and research to personalize care delivery to patients with Crohn's disease and ulcerative colitis and prevent future disease-related complications.

With our previous biomarker projects, we have discovered and validated a sensitive and specific pharmacodynamic biomarker, neutrophil CD64, to objectively monitor for gut ulcerations in patients diagnosed with IBD. This biomarker is routinely used for clinical care at our center. Additionally, we have grant support to evaluate protein biomarkers in anti-TNF non-responders to better identify which patients will respond to this type of therapy.

Personally, although growing up in a family with 12 children was a wonderful experience, I am very grateful and “busy enough” keeping up with my family of four kids. Lately, I have been enjoying my Peloton bike, walks with the family, playing sports in the backyard and vacationing on a beach anywhere. I also enjoy the challenges of adventure hikes and outdoor camping, as well as coaching my kids’ sports teams. I have slowly learned to appreciate the beauty of soccer!

Research Interests

Pediatric gastroenterology; biomarkers of treatment response and disease severity in inflammatory bowel disease.

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Gastroenterology, Inflammatory Bowel Disease

Research Divisions

Gastroenterology Hepatology and Nutrition



Blog Posts

Perspective on Alternative IBD Diets

BlogRare and Complex Conditions

Perspective on Alternative IBD Diets

By Phillip Minar, MD11/4/2016

IBD: Tips for Managing Steroid Side Effects

BlogRare and Complex Conditions

IBD: Tips for Managing Steroid Side Effects

By Phillip Minar, MD7/8/2016

My Locations

My Education

BA: Duquesne University, Pittsburgh, PA.

MD: Medical College of Wisconsin, Milwaukee, WI.

Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.

Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Certification: General Pediatrics; Pediatric Gastroenterology.

My Publications

Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Colman, RJ; Tsai, YT; Jackson, K; Boyle, BM; Noe, JD; Hyams, JS; D'Haens, GR A M; Van Limbergen, J; Rosen, MJ; Denson, LA; et al. Inflammatory Bowel Diseases. 2021; 27:1045-1051.

Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ. Pediatric Quality and Safety. 2021; 6.

Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Colman, RJ; Portocarrero-Castillo, A; Chona, D; Hellmann, J; Minar, P; Rosen, MJ. Inflammatory Bowel Diseases. 2021; 27:507-515.

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. Lyles, JL; Mulgund, AA; Bauman, LE; Su, W; Fei, L; Chona, DL; Sharma, P; Etter, RK; Hellmann, J; Denson, LA; et al. Inflammatory Bowel Diseases. 2021; 27:482-492.

Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's Disease. Haberman, Y; Minar, P; Karns, R; Dexheimer, PJ; Ghandikota, S; Tegge, S; Shapiro, D; Shuler, B; Venkateswaran, S; Braun, T; et al. Journal of Crohn's and Colitis. 2021.

A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases. Plevinsky, JM; Denson, LA; Hellmann, J; Minar, P; Rosen, MJ; Hommel, KA. Journal of Pediatric Gastroenterology and Nutrition. 2020; 71:366-370.

The Gray Zone: Adolescent and Young Adult Decision Support Needs for Ulcerative Colitis. Meisman, A; Daraiseh, NM; Minar, P; Saxe, M; Lipstein, EA. MDM Policy and Practice. 2020; 5.

Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. Colman, RJ; Mizuno, T; Meryum, S; Vinks, AA; Minar, PP. Gastroenterology. 2020; 158.

613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, BM; Chun, KY; Yang, JM; Rosen, MJ; Denson, LA; et al. Gastroenterology. 2020; 158.